Dark

PRQR
ProQR Therapeutics N.V.
stock NASDAQ

At Close

Aug 3, 2026 3:59:55 PM EDT

1.70USD-1.163%(-0.02)549,878

1.47Bid 2.11Ask 0.64Spread

Pre-market

Jul 30, 2026 9:07:30 AM EDT

1.84USD+3.399%(+0.06)0

After-hours

Aug 3, 2026 4:59:30 PM EDT

1.79USD+5.294%(+0.09)29,925

OverviewOptionsHistoricalExchangesShortsNews

Jan 31, 2022

07:39AM EST The Usher Syndrome Coalition Announces Partnership With ProQr To Support Clinical Trial Enrollment For A Potential Therapy For USH2A Mediated Retinitis Pigmentosa Benzinga

Jan 21, 2022

10:58AM EST ProQR Therapeutics Option Alert: Feb 18 $5 Calls at the Ask: 1080 @ $1.0 vs 10 OI; Earnings 2/24 Before Open [est] Ref=$5.52 Benzinga

Jan 4, 2022

07:02AM EST ProQR Announces Last Patient Has Completed 12 Month Visit In Phase 2/3 Illuminate Trial Of Sepofarsen Benzinga

07:00AM EST -- Top-line data now expected to be announced in Q1 2022 -- Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness GlobeNewswire Inc

Dec 30, 2021

07:00AM EST ProQR Therapeutics N.V.(Nasdaq:PRQR) (ProQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that it has amended its convertible debt financing agreement entered into in 2020 with Kreos Capital (Kreos) and Pontifax Medison Debt Financing (Pontifax). GlobeNewswire Inc

Dec 16, 2021

07:04AM EST ProQR Announces First Patients Dosed In Phase 2/3 Pivotal Trials Of QR-421a For USH2A Mediated Retinitis Pigmentosa Benzinga

07:00AM EST ProQR Therapeutics N.V.(Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the first patients dosed in Phase 2/3 Sirius and Celeste clinical trials of investigational RNA therapy QR-421a for people with USH2A mediated retinitis pigmentosa (RP) and Usher syndrome. GlobeNewswire Inc

Dec 15, 2021

09:32AM EST UPDATE: ProQR ClinicalTrials.gov Listing Shows 'Not yet recruiting' Benzinga

09:31AM EST ProQR National Institutes Of Health ClinicalTrials.gov Listing For Co.'s 'Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Advanced Vision Loss' Benzinga

Nov 18, 2021

04:01PM EST ProQR Therapeutics N.V. (Nasdaq: PRQR) (the Company), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a virtual Analyst Event. Management provided an in-depth review of the Companys clinical-stage programs and RNA editing technology platforms. GlobeNewswire Inc

07:55AM EST The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings Benzinga

Nov 15, 2021

10:37AM EST The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More Benzinga

Nov 11, 2021

07:00AM EST ProQR Therapeutics N.V. (Nasdaq: PRQR) (the Company), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, will webcast a virtual Analyst Event on November 18, 2021, from 12-2pm ET to highlight its clinical stage pipeline programs and the Axiomer RNA editing platform. GlobeNewswire Inc

Nov 4, 2021

07:29AM EDT ProQR Therapeutics Reports Q3 2021 Cash Equivalents Of Benzinga

07:00AM EDT ProQR Announces Third Quarter 2021 Operating and Financial Results GlobeNewswire Inc

Oct 20, 2021

08:02AM EDT ProQR Therapeutics Sponsored Study Titled 'An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (HELIA)' Posted To ClinicalTrials.Gov; Study Enrolling By Invitation Benzinga

Oct 4, 2021

08:00AM EDT -- Senior leader with extensive global rare disease commercialization experience -- Top-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022 GlobeNewswire Inc

Sep 22, 2021

09:12AM EDT ProQR Therapeutics Sponsored Study Titled 'Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3 (Fuchs Focus)' Posted To ClinicalTrials.Gov; Study Is Recruiting Benzinga

Sep 21, 2021

09:42AM EDT ProQR Therapeutics US Patent & Trademark Office Doc Showing Patent Granted For Co.'s 'Oligonucleotides to treat eye disease' Benzinga

Sep 10, 2021

07:36PM EDT Eli Lilly Reports In 13G Filing A 5.6% Stake In ProQR Therapeutics Benzinga

Sep 9, 2021

08:59AM EDT Benzinga Pro's Top 5 Stocks To Watch For Thursday, Sept. 9, 2021: ORCL, GME, HYZN, SAM, PRQR Benzinga

08:17AM EDT The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization Benzinga

05:35AM EDT The following are some of the stocks making big moves in Thursday's pre-market trading (as of 5.25 A.M. EDT). RTTNews

Sep 8, 2021

04:15PM EDT ProQR Announces Conference Call to Discuss the Axiomer GlobeNewswire Inc

04:04PM EDT ProQR Announces Axiomer RNA Editing Licensing And Research Collaboration With Lilly Benzinga

04:02PM EDT ProQR Therapeutics Shares Halted On Code News Pending Benzinga

04:01PM EDT -- Companies will collaborate to develop editing oligonucleotides directed to up tofive targets using ProQRs proprietary Axiomer RNA editing platform -- ProQR to receive $50millionconsisting of upfront payment and equity investment -- ProQR is eligible to additionally receive up to approximately $1.25billionin research,development, and commercialization milestones, plus royalties GlobeNewswire Inc

Sep 6, 2021

04:15PM EDT ProQR Announces Virtual Presentation at EURETINA 2021 GlobeNewswire Inc

Sep 3, 2021

08:00AM EDT ProQR Therapeutics N.V. (Nasdaq: PRQR) (the Company), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management will participate in the following upcoming investor conferences: GlobeNewswire Inc

Aug 11, 2021

04:30PM EDT ProQR Therapeutics N.V. (Nasdaq: PRQR) (the Company), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management will present at the upcoming HC Wainwright Ophthalmology Virtual Conference. The presentation will be available on demand on August 17, 2021, at 7:00 am EDT. GlobeNewswire Inc

Aug 9, 2021

09:09AM EDT Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $18 Benzinga

Aug 5, 2021

07:25AM EDT ProQR Therapeutics Reports Q2 Sales 243K, EPS (0.24) Down From (0.08) YoY Benzinga

07:00AM EDT -- Top-line data from Phase 2/3 pivotalIlluminatetrial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022 -- QR-421a pivotal Sirius and Celeste Phase 2/3 trials in Usher syndrome and retinitis pigmentosa expected to start by year end 2021 -- Initial clinical data from Phase 1/2 Aurora trial of QR-1123 for autosomal dominant retinitis pigmentosa expected in Q4 2021 GlobeNewswire Inc

Jun 10, 2021

07:00AM EDT ProQR Therapeutics N.V. (Nasdaq: PRQR) (the Company), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management will present during a fireside chat at the upcoming JMP Securities Life Sciences Conference. The presentation will be webcast live on June 17, 2021, from 3:00 3:25pm EDT. GlobeNewswire Inc

May 6, 2021

07:34AM EDT ProQR Therapeutics Q1 EPS (0.25), Up From Benzinga

07:00AM EDT ProQR Announces First Quarter 2021 Operating and Financial Results GlobeNewswire Inc

May 4, 2021

10:10AM EDT ProQR Therapeutics shares were trading higher after the company, and Yarrow Biotechnology, announced an exclusive worldwide license and discovery collaboration for an undisclosed target. Benzinga

09:35AM EDT ProQR Therapeutics Stock Is Trading Higher On Antisense Oligonucleotide Development Pact Benzinga

07:22AM EDT ProQR Therapeutics And Yarrow Biotechnology Announce Exclusive Worldwide License And Discovery Collaboration For Undisclosed Target; ProQR Eligible To Receive Upfront And Milestone Payments Of $115M Benzinga

07:00AM EDT -- Yarrow Biotechnology, Inc., a newly formed biotechnology company backed by RTW Investments, LP, will lead development oftheprogram -- ProQR Therapeutics is eligible to receive upfront and milestone payments of up to $115 million plusroyalties on future sales byYarrow for an exclusive worldwide license and discovery collaboration on a non-ophthalmology target GlobeNewswire Inc

May 3, 2021

02:59PM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2021 Benzinga

09:31AM EDT Stifel Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target of $20 Benzinga

Apr 23, 2021

07:02AM EDT ProQR Therapeutics To Present Data From Co.'s Phase 1/2 InSight Extension Trial Of Sepofarsen At Association For Research In Vision And Ophthalmology May 6, 2021 At 5:15 p.m. EDT Benzinga

07:00AM EDT ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen GlobeNewswire Inc

Apr 22, 2021

07:00AM EDT ProQR Therapeutics N.V. (Nasdaq: PRQR) (the Company), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that Company management will host 1x1 meetings through the Kempen Life Sciences Conference 2021 Thematic Virtual Series on April 28, 2021. GlobeNewswire Inc

Apr 20, 2021

07:00AM EDT ProQR Therapeutics N.V. (Nasdaq: PRQR) (the Company), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced the Annual General Meeting of Shareholders will take place on Wednesday, May 19, 2021 at 16:00 CET (10:00am EDT) via videoconference. GlobeNewswire Inc

Apr 13, 2021

04:16PM EDT ProQR Therapeutics Highlights Publication In 'Nature Medicine' Titled 'Durable vision improvement after a single treatment with antisense oligonucleotide sepofarsen: a case report' Benzinga

04:15PM EDT ProQR Announces Publication in Nature Medicine for Sepofarsen in GlobeNewswire Inc

Apr 5, 2021

04:15PM EDT ProQR Announces Closing of Underwritten Public Offering of GlobeNewswire Inc

Apr 2, 2021

04:15PM EDT ProQR Therapeutics N.V.(Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual presentation at the Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) held April 9-11, 2021. GlobeNewswire Inc

Mar 31, 2021

07:41AM EDT The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO Benzinga

Mar 30, 2021

10:25PM EDT ProQR Prices $90 Million Underwritten Public Offering of Ordinary GlobeNewswire Inc

04:15PM EDT ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares; No Terms Disclosed Benzinga

04:05PM EDT ProQR Announces Proposed Underwritten Public Offering of Ordinary GlobeNewswire Inc

Mar 26, 2021

07:28AM EDT The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs Benzinga

Mar 24, 2021

08:59AM EDT The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping Benzinga

08:16AM EDT ProQR Therapeutics Is Trading Higher On Positive QR-421a Data In Usher Syndrome Benzinga

07:22AM EDT ProQR Therapeutics Announces Positive Results From Phase 1/2 Stellar Trial Of QR-421a In Usher Syndrome RTTNews

07:03AM EDT ProQR Announces Results From Trial Of QR-421a In Usher Syndrome; QR-421a 'demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT)' Benzinga

07:00AM EDT -- QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT) -- QR-421a observed to be well tolerated with no serious adverse events reported -- Two pivotal Phase 2/3 trials are expected to start by the end of 2021 -- Management to host a conference call today at 8:15am EDT GlobeNewswire Inc

Mar 18, 2021

01:25AM EDT Today's Daily Dose brings you news about Cannabics' drug candidate RCC-33 prolonging survival rate in mice inoculated with human colorectal cancer cells, encouraging data of Immatics' ACTengine program, and disappointing results from Translate Bio's cystic fibrosis trial. RTTNews

Mar 17, 2021

07:17AM EDT ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome Benzinga

07:09AM EDT ProQR To Present And Discuss Results From Its Phase 1/2 Stellar Trial Of QR-421a RTTNews

07:00AM EDT ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher GlobeNewswire Inc

Mar 2, 2021

04:35PM EST ProQR To Present At HC Wainwright Global Life Sciences Conference Mar. 9 Benzinga

04:30PM EST ProQR Announces Webcast of Presentation at Upcoming HC Wainwright GlobeNewswire Inc

Feb 25, 2021

07:21AM EST ProQR Therapeutics Q4 2020 EPS (0.26) Vs Benzinga

07:00AM EST ProQR Announces Fourth Quarter and Full Year 2020 Operating and GlobeNewswire Inc

Feb 16, 2021

04:30PM EST ProQR Announces Expert Perspectives Call on Disease Education and GlobeNewswire Inc

Jan 26, 2021

02:19PM EST ProQR Therapeutics II B.V. Leiden N/A NL Issued U.S. Patent #10,900,041 'Antisense oligonucleotides for use in treating Alzheimer's disease' Benzinga

Jan 7, 2021

07:00AM EST -- Top-line results expected H1 2022 -- Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness GlobeNewswire Inc

Dec 18, 2020

07:00AM EST ProQR Announces Webcast of Presentation at Upcoming HC Wainwright GlobeNewswire Inc

Nov 18, 2020

07:00AM EST ProQR to Present at 3rd Annual Evercore ISI Virtual HealthCONx GlobeNewswire Inc

Nov 16, 2020

07:08AM EST ProQR Q3 EPS (0.26) Benzinga

07:00AM EST ProQR Announces Third Quarter 2020 Operating and Financial Results GlobeNewswire Inc

Nov 13, 2020

07:40AM EST The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 2, 2020

04:14PM EST ProQR Therapeutics Shares Higher After Hours As Hearing Cantor Assuming Coverage With Overweight Rating, $22 Price Target Benzinga

07:00AM EST ProQR Therapeutics N.V.(Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced virtual poster presentations at the Annual Meeting of the American Academy of Ophthalmology (AAO) held November 13-15, 2020. GlobeNewswire Inc

Oct 29, 2020

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

Oct 21, 2020

08:04AM EDT The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings Benzinga

Oct 20, 2020

08:17AM EDT The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger Benzinga

Oct 5, 2020

07:13AM EDT ProQR Appoints Naveed Shams As Chief Scientific Officer RTTNews

07:00AM EDT ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer Benzinga

Sep 24, 2020

04:10PM EDT ProQR Therapeutics N.V.(Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced virtual presentations at the Ophthalmology Futures Retina Forum, European Society of Retina Specialists (Euretina) congress and the Annual Meeting of the American Academy of Optometry (AAOpt). GlobeNewswire Inc

Sep 3, 2020

07:00AM EDT ProQR Therapeutics N.V. (Nasdaq: PRQR) (the Company), a company dedicated to changing lives through the creation of transformative RNA medicines for inherited retinal diseases (IRDs), today announced that Company management will participate in the following upcoming investor conferences: GlobeNewswire Inc

Aug 11, 2020

07:53AM EDT Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $20 Benzinga

Aug 6, 2020

05:37PM EDT ProQR Therapeutics Q2 EPS (0.08) Up From Benzinga

Jul 21, 2020

07:00AM EDT ProQR Strengthens Scientific Advisory Board with Leaders in GlobeNewswire Inc

Jul 14, 2020

04:34PM EDT ProQR Announces $30M Strategic Convertible Debt Financing Agreement With Pontifax Ventures Benzinga

04:30PM EDT -- Extends ProQRs cash runway into 2023 -- ProQR can trigger conversion of the debt to equity at $7.88 per share, under certain conditions GlobeNewswire Inc

Jul 13, 2020

04:33PM EDT ProQR To Host 'Expert Perspectives' Call On LCA10 And Sepofarsen Jul. 20 Benzinga

04:30PM EDT ProQR Announces Expert Perspectives Call on LCA10 and Sepofarsen GlobeNewswire Inc